ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
Capstone Therapeutics Corporation (QB)

Capstone Therapeutics Corporation (QB) (CAPS)

3.20
0.00
(0.00%)
마감 24 11월 6:00AM

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

주요 통계 및 세부정보

가격
3.20
매수가
3.00
매도가
3.20
거래량
1
0.00 일간 변동폭 0.00
3.20 52주 범위 5.25
market_cap
전일 종가
3.20
개장가
-
최근 거래 시간
1
@
3.02
마지막 거래 시간
재정 규모
-
VWAP
-
평균 볼륨(3m)
176
발행 주식
157,610
배당수익률
-
주가수익률
-0.09
주당순이익(EPS)
-36.39
매출
48.35M
순이익
-5.74M

Capstone Therapeutics Corporation (QB) 정보

Capstone Therapeutics Corp. was a biotechnology company committed to developing a pipeline of novel therapeutic peptides aimed at helping patients with under-served medical conditions. Effective April 1, 2020, the Company merged with Totalstone, LLC, a materials distribution company that distributes... Capstone Therapeutics Corp. was a biotechnology company committed to developing a pipeline of novel therapeutic peptides aimed at helping patients with under-served medical conditions. Effective April 1, 2020, the Company merged with Totalstone, LLC, a materials distribution company that distributes masonry stone products in the Midwest and Northeast United States, under the trade names of Instone and Northeast Masonry Distributors' and which going forward will be the Company's primary business activity. 더 보기

섹터
Electromedical Apparatus
산업
Surgical,med Instr,apparatus
웹사이트
본부
Wilmington, Delaware, USA
설립됨
2004
Capstone Therapeutics Corporation (QB) is listed in the Electromedical Apparatus sector of the OTC 시장 with ticker CAPS. The last closing price for Capstone Therapeutics (QB) was US$3.20. Over the last year, Capstone Therapeutics (QB) shares have traded in a share price range of US$ 3.20 to US$ 5.25.

Capstone Therapeutics (QB) currently has 157,610 shares in issue. The market capitalisation of Capstone Therapeutics (QB) is US$504,352 . Capstone Therapeutics (QB) has a price to earnings ratio (PE ratio) of -0.09.

CAPS 최신 뉴스

EDISON EQUITY RESEARCH - CAPSTONE THERAPEUTICS

EDISON EQUITY RESEARCH: CAPSTONE THERAPEUTICS - FOCUS ON ACUTE PANCREATITIS Capstone is investigating a promising new indication for its Apo-E mimetics triglyceride lowering in acute pancreatitis...

EDISON EQUITY RESEARCH - CAPSTONE THERAPEUTICS

EDISON EQUITY RESEARCH: CAPSTONE THERAPEUTICS - INITIAL PROOF-OF-CONCEPT ESTABLISHED AEM-28 has demonstrated significant reductions in both VLDL and triglycerides in the Phase I/II programme...

EDISON EQUITY RESEARCH - CAPSTONE THERAPEUTICS

EDISON EQUITY RESEARCH - CAPSTONE THERAPEUTICS: FIRST HUMAN LIPID BIOMARKER TRENDS Early data in healthy volunteers have demonstrated trends in favour of AEM-28 on a number of lipid biomarkers...

Capstone Therapeutics Announces Initiation of Dosing for AEM-28 Phase 1b/2a Human Clinical Trial in Refractory Hypercholester...

TEMPE, Ariz., June 11, 2014 (GLOBE NEWSWIRE) -- Capstone Therapeutics (OTCQB:CAPS) ("the Company") and its joint venture affiliate, LipimetiX Development, LLC ("JV"), announced today the...

Capstone Therapeutics Announces Operating Update Conference Call

TEMPE, Ariz., May 16, 2014 (GLOBE NEWSWIRE) -- Capstone Therapeutics (OTCQB:CAPS); (the "Company"), will hold a conference call and webcast on Wednesday, May 21, 2014 at 4:30 pm EDT. The call may...

Capstone Therapeutics Announces Initiation of Dosing for AEM-28 Phase 1 Human Clinical Trial in LDL/non-HDL Cholesterol Reduc...

TEMPE, Ariz., April 8, 2014 (GLOBE NEWSWIRE) -- Capstone Therapeutics (OTCQB:CAPS) ("the Company") and its joint venture affiliate, LipimetiX Development, LLC ("JV"), announced today the...

Capstone Therapeutics Announces Operating Update Conference Call, Planned Initiation of AEM-28 Phase 1 Study and Fiscal Year ...

TEMPE, Ariz., March 27, 2014 (GLOBE NEWSWIRE) -- Capstone Therapeutics (OTCQB:CAPS) ("the Company") and its joint venture affiliate, LipimetiX Development, LLC ("JV"), today will hold a...

Capstone Therapeutics Announces Operating Update Conference Call

TEMPE, Ariz., March 24, 2014 (GLOBE NEWSWIRE) -- Capstone Therapeutics (OTCQB:CAPS); (the "Company"), will hold a conference call and webcast on Thursday, March 27, 2014 at 4:30 pm EDT. The call...

Capstone Therapeutics Announces a LipimetiX Development, LLC Presentation at the American Heart Association Scientific Sessio...

TEMPE, Ariz. and BOSTON, Nov. 19, 2013 (GLOBE NEWSWIRE) -- Capstone Therapeutics' (OTCQB:CAPS) joint venture, LipimetiX Development, LLC, today announced the presentation of pre-clinical data...

Capstone Therapeutics Will Provide an Operating Update and Announces Second Quarter 2013 Financial Results

TEMPE, Ariz., Aug. 14, 2013 (GLOBE NEWSWIRE) -- Capstone Therapeutics (OTCQB:CAPS) (the "Company"), today will hold a conference call and webcast to provide an operating update and announced...

기간변동변동 %시가고가저가평균 일일 거래량VWAP
10000000CS
40000000CS
12-0.8-20443.21763.50426829CS
26-0.9-21.95121951224.14.53.22603.9069929CS
52-2-38.46153846155.25.253.22624.15472988CS
156-14.05-81.449275362317.2537.53.225216.59382193CS
260-10.9-77.30496453914.137.53.227818.74888566CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
NEPTFNeptune Wellness Solutions Inc (CE)
US$ 0.0238
(2,379,900.00%)
13.46k
CNVIFConavi Medical Corporation (PK)
US$ 0.58
(82,757.14%)
2.25k
FUNFFFansUnite Entertainment Inc (CE)
US$ 0.00055
(54,900.00%)
342.7k
RQHTFReliq Health Technologies Inc (CE)
US$ 0.0003
(29,900.00%)
219.11k
ELOXEloxx Pharmaceuticals Inc (CE)
US$ 0.0001
(9,900.00%)
1.53k
FDVXFFenixOro Gold Corporation (CE)
US$ 0.000001
(-100.00%)
10k
TMPOQTempo Automation Holdings Inc (CE)
US$ 0.000001
(-99.98%)
200
HLLPFHello Pal International Inc (CE)
US$ 0.000001
(-99.90%)
6k
MOTSMotus GI Holdings Inc (CE)
US$ 0.000001
(-99.88%)
649
BTAEFBeta Energy Corporation (CE)
US$ 0.000001
(-99.67%)
655
RSHNRushNet Inc (PK)
US$ 0.00015
(-25.00%)
502.31M
EARIEntertainment Arts Research Inc (PK)
US$ 0.0001
(0.00%)
428.38M
ASTAAstra Veda Corporation (PK)
US$ 0.0002
(-33.33%)
364.38M
RDARRaadr Inc (PK)
US$ 0.0009
(50.00%)
276.07M
CGACCode Green Apparel Corp (PK)
US$ 0.00065
(44.44%)
225.16M

CAPS Discussion

게시물 보기
infamous infamous 5 년 전
wow this stock has been the biggest pharma scam i maybe have ever seen! RS and now like 99% down in premarket to .013. what a joke this stock is. I bet they cant WAIT to add to the float and start selling again. yuk
👍️0
Renee Renee 5 년 전
CAPS one for 1,000 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
👍️0
Werbe Werbe 5 년 전
NITE with 1.5 mil bid up @ .014
👍️0
eugenecj eugenecj 8 년 전
WOW.Insider buy 50,000 @ 7.First in a while
👍️0
eugenecj eugenecj 8 년 전
HAPPY HOLIDAYS TO ALL
👍️0
stocksstockstocks stocksstockstocks 8 년 전
Nice :)
👍️0
eugenecj eugenecj 8 년 전
This could be big
👍️0
eugenecj eugenecj 8 년 전
Capstone Therapeutics Corp. (OTCQB:CAPS) ("the Company") and LipimetiX Development, Inc., the Company's drug development joint venture ("JV") announced today that the JV's lead commercial drug candidate, AEM-28-14, showed substantial and statistically-significant LDL cholesterol (LDLc) reductions in a hypercholesterolemic primate study at Wake Forest University. Following a single IV administration of escalating doses up to 5mg/kg, LDLc exhibited a mean reduction of 64% from baseline at 24 hours, 46% from baseline at 3 days and 16% from baseline at 7 days, despite the study animals remaining on a high fat/cholesterol diet through the full study.

A PDF accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/065505f4-bc99-4efc-b76d-b7d16c876ed3

Dennis I. Goldberg, PhD, President and CEO of LipimetiX Development, Inc. stated "AEM-28-14 has shown clinically-relevant levels of cholesterol reduction in multiple validated preclinical models and may be the most powerful lipid reduction agent yet discovered. Primate models are often predictive of a molecule's therapeutic performance in humans. Accordingly, we see the LDLc reduction in this primate model as consistent with the benefits that we hope to deliver to Homozygous Familial Hypercholesterolemia (HoFH) patients...powerful cholesterol lowering combined with duration of effect."

The JV's development goals are to conduct Phase 1a, 1b, and 2a human clinical trials with AEM-28-14 to show an acceptable safety profile and cholesterol reduction efficacy in HoFH, an orphan genetic disease characterized by extremely high LDLc due to inherited defects in the LDL receptor pathway from both parents. The hypercholesterolemia associated with HoFH is difficult to treat since it is refractory to drugs and biologics, such as statins and PCSK9 inhibitors, that increase the expression and functionality of the LDL receptor in normal patients.

Chimeric Apolipoprotein E Mimetic Peptides

Apolipoprotein E (Apo E) is in a class of protein that occurs throughout the body. Apo E is essential for the normal metabolism of cholesterol and triglycerides. After a meal, the postprandial (or post-meal) lipid load is packaged in lipoproteins and secreted into the blood stream. Apo E targets cholesterol and triglyceride-rich lipoproteins to specific receptors in the liver, decreasing these levels in the blood. Defective metabolism of cholesterol and triglyceride-rich lipoprotein remnants plays an important role in the development of diseases of the coronary, cerebral and peripheral arteries often leading to heart attack and stroke.

The University of Alabama at Birmingham ("UAB") scientists patented the first chimeric Apo E mimetic peptide in 1999, reducing the 299 amino acid native Apo E into a 28 amino acid, dual domain peptide that can be delivered therapeutically. One domain inserts into a lipoprotein surface and the second domain binds to the Apo E receptors in the liver. In 2010, our JV's founding scientist, Dr. Dennis Goldberg, obtained worldwide right to patents for Apo E mimetic peptides from the UAB Research Foundation ("UABRF"). The JV has an Exclusive License Agreement with the University of Alabama at Birmingham Research Foundation for AEM-28 and its analogs.

The JV has continued research in to a new generation of chimeric Apo E peptides and has discovered AEM-28-14, resulting in a USPTO and PCT patent filing in 2015 supporting claims for a broad domain of Apo E mimetic peptides. AEM-28-14 was found to be more potent (as tested in multiple
👍️0
RealGenius RealGenius 9 년 전
$0.02 per share cash. No current research underway. Will be at Rodman & Renshaw looking for investment to continue work.
👍️0
infamous infamous 9 년 전
This stock should imo be trading sub penny. Arent they going through their money like water for research that amounts to nothing?
👍️0
stocktrademan stocktrademan 9 년 전
$CAPS recent news/filings

bullish
charts that are focused on long term growth and are not affected by earnings reports

## source: finance.yahoo.com

Thu, 23 Jul 2015 12:03:11 GMT ~ CAPSTONE THERAPEUTICS CORP. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits


read full: http://biz.yahoo.com/e/150723/caps8-k.html
*********************************************************

Thu, 23 Jul 2015 12:00:00 GMT ~ Capstone Therapeutics Announces Patent Application for Novel, More Potent Chimeric Apo E Mimetic Peptides

[GlobeNewswire] - TEMPE, Ariz. -- Capstone Therapeutics Corp. (OTCQB:CAPS) ("the Company") and its joint venture affiliate, LipimetiX Development, Inc. ("JV"), announced today the conversion of a provisional ...

read full: http://finance.yahoo.com/news/capstone-therapeutics-announces-patent-application-120000212.html
*********************************************************

Mon, 22 Jun 2015 16:53:30 GMT ~ CAPSTONE THERAPEUTICS CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a


read full: http://biz.yahoo.com/e/150622/caps8-k.html
*********************************************************

Fri, 19 Jun 2015 20:30:00 GMT ~ Capstone Therapeutics Corp. Q1 2015 Operating Update Call scheduled for 4:30 pm ET today


read full: http://biz.yahoo.com/cc/9/144899.html
*********************************************************

Tue, 02 Jun 2015 15:43:03 GMT ~ CAPSTONE THERAPEUTICS CORP. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits


read full: http://biz.yahoo.com/e/150602/caps8-k.html
*********************************************************

$CAPS charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$CAPS company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/CAPS/company-info
Ticker: $CAPS
OTC Market Place: OTCQB
CIK code: 0000887151
Company name: Capstone Therapeutics Corp
Company website: http://www.capstonethx.com
Incorporated In: DE, USA

Business Description: Capstone Therapeutics Corp. is a biotechnology company committed to developing a pipeline of novel therapeutic peptides aimed at helping patients with under-served medical conditions.

$CAPS share structure

## source: otcmarkets.com

Market Value: $8,585,936 a/o Jul 27, 2015
Shares Outstanding: 40,885,411 a/o Mar 13, 2015
Float: Not Available
Authorized Shares: 100,000,000 a/o Mar 13, 2015
Par Value: 0.0005

$CAPS extra dd links

Company name: Capstone Therapeutics Corp
Company website: http://www.capstonethx.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CAPS+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CAPS+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CAPS+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CAPS/news - http://finance.yahoo.com/q/h?s=CAPS+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CAPS/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CAPS/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CAPS+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CAPS
DTCC (dtcc.com): http://search2.dtcc.com/?q=Capstone+Therapeutics+Corp&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Capstone+Therapeutics+Corp
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Capstone+Therapeutics+Corp&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.capstonethx.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.capstonethx.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.capstonethx.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CAPS
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000887151&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CAPS/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CAPS/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CAPS&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CAPS
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CAPS/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CAPS+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CAPS+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CAPS
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CAPS
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CAPS+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CAPS/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CAPS+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CAPS.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CAPS
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CAPS/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CAPS/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CAPS
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CAPS
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CAPS:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CAPS
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CAPS



$CAPS DD Notes ~ http://www.ddnotesmaker.com/CAPS
👍️0
infamous infamous 9 년 전
No run! Nor will there ever be. These guys go through money like water
👍️0
skipsvalue skipsvalue 9 년 전
Big news out could see run watch for pre market buys
👍️0
infamous infamous 10 년 전
wow last post here was back in feb! Totally no demand here!
👍️0
deadjim deadjim 11 년 전
nope. ill look. I still don't like you. so quit messaging me. later.
👍️0
infamous infamous 11 년 전
Caps will be a dollar stock soon. Did yu see how many shares are being acquired ?
👍️0
deadjim deadjim 11 년 전
no, I don't care, actually. I did mid .20s a looong time ago.
👍️0
infamous infamous 11 년 전
oh i get it. you just said you WERE long. You must have sold WAY too early then. Sucks to be you.
👍️0
deadjim deadjim 11 년 전
you're an idiot. if you read all my posts here you see I was long. these posts were over a year ago.
👍️0
infamous infamous 11 년 전
And now the stock is in the .30s with BVF buying millions of shares over the last several months. go away idiot!
👍️0
JD400 JD400 11 년 전
CAPS+48.00% Nice Rise Today~
👍️0
deadjim deadjim 12 년 전
.19x.20
👍️0
deadjim deadjim 12 년 전
.19c close.. On air. .. Probably air everyday
👍️0
deadjim deadjim 12 년 전
Not watching anything other than price. Don't care. Will sell and be gone for ever
👍️0
infamous infamous 12 년 전
Did yu look at today though? All these bullsht options awarded to these thieves?
👍️0
The Night Stalker The Night Stalker 12 년 전
im in on SBFM it looks better chart wise than CAPS
👍️0
The Night Stalker The Night Stalker 12 년 전
volumes picking up here
👍️0
The Night Stalker The Night Stalker 12 년 전
a run is brewing here
👍️0
The Night Stalker The Night Stalker 12 년 전
was going to make this my next sleeper but i changed my mind, have a better one than this next.
👍️0
deadjim deadjim 12 년 전
feels like it. i used to trade this back in the day. traded like a snail then too. may just bore everyone to death
👍️0
The Night Stalker The Night Stalker 12 년 전
nice, im thinking this wakes up soon.
👍️0
The Night Stalker The Night Stalker 12 년 전
goldon cross forming
👍️0
deadjim deadjim 12 년 전
another insider buy just posted 175K
👍️0
The Night Stalker The Night Stalker 12 년 전
volumes hitting here, this is a sleeper.
👍️0
deadjim deadjim 12 년 전
CAPS is a good example of what happens when you have NO SELLERS. The stock doesn't move! Sitting at .15x.18 and now .155x.20.. you think buyers are going to buy a 30% intra spread? Come on now. You have no sellers, bidders sitting there, stock is motionless - people think sellers are a bad thing - this is what creates a market, people. Think outside the box and ignore the general fallacies of typical ihub traders.
👍️0
deadjim deadjim 12 년 전
$CAPS was pretty much .152x.18 all day today
👍️0
xr_biotech_consult xr_biotech_consult 12 년 전
have it on close watch, may i will entry
👍️0
deadjim deadjim 12 년 전
Took some .165 $CAPS
👍️0
Roy London Roy London 12 년 전
whats up?!
👍️0
infamous infamous 12 년 전
Anyone here notice that yahoo CAPS message board is cancelled? Why so?
👍️0
surf1944 surf1944 13 년 전
http://quotes.barrons.com/caps/ownership
👍️0
infamous infamous 13 년 전
UH OH CAPS is selling off today i think based on the last paragraph of the news about the litigation still being a problem.
👍️0
surf1944 surf1944 13 년 전
http://www.form4oracle.com/company/orthologic-corp-caps.pk/company-transactions?id=7152
👍️0
surf1944 surf1944 13 년 전
http://biz.yahoo.com/e/111110/caps.pk10-q.html
👍️0
infamous infamous 13 년 전
Looks like bankrupsy ahead for this company! they have to cut staff, and they are worried about their cash position. Plus, they are praying to get a partner thats going to invest in them even when the ends of the trials dont pan out. goodbye Jock strap
👍️0
surf1944 surf1944 13 년 전
http://www.insidercow.com/history/company.jsp?company=caps&B1=Search!
👍️0
surf1944 surf1944 13 년 전
http://www.secform4.com/insider-trading/887151.htm
👍️0
TheProfit TheProfit 13 년 전
oh, well thx for the update
👍️0
infamous infamous 13 년 전
Nope, CC sucked as usual and they are burning through their cash too quickly. Also, I was the only one who asked questions( i think there was noone else listening to the CC), and I didnt like the answers to my questions! company blows!
👍️0
TheProfit TheProfit 13 년 전
Anything good there? Wasnt able to hear it myself. TIA EB.
👍️0

최근 히스토리

Delayed Upgrade Clock